Wellington Management Group LLP Trims Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Wellington Management Group LLP decreased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 13.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 63,513 shares of the biopharmaceutical company's stock after selling 9,807 shares during the quarter. Wellington Management Group LLP's holdings in TG Therapeutics were worth $1,912,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. purchased a new position in shares of TG Therapeutics in the fourth quarter valued at $30,000. Quadrant Capital Group LLC grew its position in shares of TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 975 shares in the last quarter. Blue Trust Inc. grew its position in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Trading Up 1.9%

Shares of NASDAQ TGTX traded up $0.76 during midday trading on Friday, reaching $40.06. The company had a trading volume of 2,135,380 shares, compared to its average volume of 2,975,380. TG Therapeutics, Inc. has a one year low of $15.16 and a one year high of $46.48. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm's fifty day moving average price is $37.21 and its 200-day moving average price is $34.69. The stock has a market cap of $6.36 billion, a PE ratio of -400.56 and a beta of 1.94.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same quarter in the prior year, the firm earned ($0.07) EPS. The firm's revenue for the quarter was up 90.4% on a year-over-year basis. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.